UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34705 ___________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) ________________________ ...

Codexis, Inc. (NASDAQ:CDXS) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants John Nicols – President and Chief Executive Officer Ross Taylor – Senior Vice President and Chief Financial Officer Brendan Strong – Investor Relations, Argot Partners Conference Call Participants Steven Mah – Cowen Brandon Couillard – Jefferies Matthew Hewitt – Craig-Hallum Capital Group Evan Karev – Piper Sandler Operator Welcome to the Codexis First Quarter 2022, Earnings Conference Call. [Operator In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-34705 Codexis, Inc. (Exact name of registrant as specified in its charter) Registrant's telephone number, including area code: (650) 42 ...

CODEXIS® We engineer enzymes to improve health… of people and the planet Q4 & FY'2021 Results February 24, 2022 Forward Looking Statements 2 • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achieveme ...

Codexis, Inc. (NASDAQ:CDXS) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Brendan Strong - Argot Partners John Nicols - President & Chief Executive Officer Ross Taylor - Senior Vice President & Chief Financial Officer Conference Call Participants Brandon Couillard - Jefferies Matt Hewitt - Craig-Hallum Capital Group Jacob Johnson - Stephens Swayampakula Ramakanth - H.C. Wainwright Operator Greetings and welcome to the Codexis Fourth Quarter and Full Year 2021 Earnings Co ...

CODEXIS® We engineer enzymes to improve health… of people and the planet Corporate Presentation November 2021 Forward Looking Statements 2 • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties, including Codexis' guidance on 2021 total revenues, product revenues and product gross margin. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and othe ...

CODEXIS® We engineer enzymes to improve health… of people and the planet Q3 2021 Financial Results November 4, 2021 Forward Looking Statements 2 • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties, including Codexis' guidance on 2021 total revenues, product revenues and product gross margin. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties an ...

Codexis, Inc. (NASDAQ:CDXS) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Stephanie Marks – Investor Relations John Nicols – President and Chief Executive Officer Ross – Chief Financial Officer Conference Call Participants Brandon Couillard – Jefferies Matt Hewitt – Craig Hallum Jacob Johnson – Stephens Operator Welcome to the Codexis Q3 2021 Earnings Conference Call. All lines have been placed on a listen-only mode and the floor will be open for questions and comments fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34705 ___________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) ____________________ ...

CODEXIS® We engineer enzymes to improve health… of people and the planet Corporate Presentation September 2021 Forward Looking Statements 2 • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achievemen ...